Linical Co., Ltd.

Tokyo Stock Exchange 2183.T

Linical Co., Ltd. Price to Sales Ratio (P/S) on January 29, 2025: 0.60

Linical Co., Ltd. Price to Sales Ratio (P/S) is 0.60 on January 29, 2025, a -30.10% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Linical Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 0.84 on January 30, 2024, which is 40.83% above the current Price to Sales Ratio (P/S).
Linical Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 0.58 on December 24, 2024, which is -2.95% below the current Price to Sales Ratio (P/S).
Linical Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 0.70.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Tokyo Stock Exchange: 2183.T

Linical Co., Ltd.

CEO	Mr. Kazuhiro Hatano
IPO Date	Oct. 27, 2008
Location	Japan
Headquarters	Shin-Osaka Brick Building
Employees	662
Sector	Health Care
Industries Pharmaceuticals Research & Consulting

Description

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.

Key trends

Past 5 years